In BRAFV600E-mutated melanoma, the combination of BRAF and MEK inhibitors has led to high response rates (70%) and rapid response induction and symptom control, with a significant prolongation of progression-free survival [183, 184]. The gene discussed is MAP2K7; the disease is melanoma.